A single-dose experimental gene therapy has been reported to lower "bad" cholesterol by 52%, according to multiple Arabic-language news outlets including Al Bayan. The reports, published Monday, describe the treatment as a one-time intervention for managing high cholesterol.
The coverage, which draws on early-stage trial data, indicates that the therapy also reduced triglycerides, a type of fat in the blood linked to cardiovascular risk. Al Bayan and other outlets, such as Okaz and Al Khaleej, framed the results as a potential breakthrough for patients with elevated cholesterol who struggle with daily medication regimens.
The treatment is described as an investigational gene therapy, meaning it has not yet been approved for widespread clinical use. The reported 52% reduction in low-density lipoprotein (LDL) cholesterol—often called "bad" cholesterol—comes from a single administration, which would mark a significant departure from current standard care. Existing treatments, such as statins, typically require daily oral dosing and can be associated with adherence challenges.
According to the summarized reporting, the therapy works by targeting the underlying genetic pathways that regulate cholesterol production or clearance. The reports did not specify the exact mechanism, trial size, or patient population, nor did they detail potential side effects or the timeline for regulatory review. The findings appear to come from early-phase human trials, and the outlets did not indicate whether the data has been peer-reviewed or published in a medical journal.
The coverage suggests that if the therapy proves safe and effective in larger studies, it could offer an alternative for patients at high risk of heart disease who cannot tolerate or consistently take conventional cholesterol-lowering drugs. However, experts quoted in the original reports were not available in the provided material, so no independent clinical commentary was included.
What to watch next: Whether the developers release full trial data and initiate larger Phase 3 studies to confirm the durability and safety of the single-dose effect.
